Cancer Therapy Matching: AI Cell Type Identification
- An innovative algorithm called TACIT promises to accelerate the identification of effective cancer treatments for patients.
- The technology aims to refine patient selection for clinical trials, ensuring the right individuals receive the most appropriate treatments.
- Beyond clinical trials, TACIT leverages RNA markers to guide pharmacological care.
Algorithm IDs Cancer Therapies, Improves Clinical Trials
An innovative algorithm called TACIT promises to accelerate the identification of effective cancer treatments for patients. Developed at Virginia Commonwealth University, TACIT analyzes cell types to match individuals with the most suitable therapies, potentially transforming clinical trials and pharmacological interventions.
The technology aims to refine patient selection for clinical trials, ensuring the right individuals receive the most appropriate treatments. Dr. Andrew Byrd,a researcher involved in the project,emphasized TACIT’s ability to prevent the inclusion of unsuitable patients in trials,a current limitation in the field.
Beyond clinical trials, TACIT leverages RNA markers to guide pharmacological care. According to Dr. Huynh Liu, the algorithm can predict drug responses and outcomes, offering patients alternative treatment options even if they are ineligible for a trial. The researchers envision mapping FDA-approved drugs onto tissue samples, providing immediate, viable options for patients.
TACIT’s versatility extends across various spatial biology applications, integrating diverse datasets to enhance its analytical capabilities. Byrd likened TACIT to a “Rosetta Stone,” capable of harmonizing diffrent data types, from proteins to organ systems, across various diseases.
The technology also incorporates a novel approach to cell multi-omics, linking slide proteomics and transfer proteomics to study multiple markers simultaneously, a capability previously limited to single-cell omics.
“You could use TACIT to get the right patient into the trial—and as importantly—not put the wrong patient in the trial. Right now, we don’t have a very good tool for that, but this is quite powerful to do it,” Byrd said.
What’s next
The researchers plan to expand TACIT’s applications, exploring its potential in various organ systems and disease types, further solidifying its role in personalized medicine and drug discovery.